Emcure Pharmaceuticals Q4 Results: Date, Dividend Details, Earnings Call Schedule And More
The company has scheduled an earnings call with investors and analysts on May 22 at 3:30 p.m. to discuss the Q4 and FY25 results.
Emcure Pharmaceuticals Ltd. is scheduled to release its earnings reports for the fourth quarter and the full financial year 2024-25 this week.
It is one of India’s leading pharmaceutical companies with a presence in over 70 countries. Its portfolio includes biotherapeutics, antiretrovirals and diabetes medicines. It has five research and development centres across India.
Here’s everything you need to know about Emcure Pharmaceuticals’ Q4 and FY25 result announcement.
Emcure Pharmaceuticals Q4 Results: Date And Dividend Details
A meeting of Emcure Pharma’s Board of Directors is scheduled on May 22 to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 2025, the company informed the stock exchanges in a filing last week.
The Board will also consider the recommendation of final dividend, if any, for FY25.
Emcure Pharmaceuticals Q4 Results: Trading Window Closure
The trading window for dealing in securities of the company is closed for designated persons and their relatives from April 1 to May 24. This is being done to comply with the SEBI rules to prevent insider trading.
Emcure Pharmaceuticals Q4 Results: Earnings Call
The company has scheduled an earnings call with investors and analysts on May 22 from 3:30 p.m. to 4:30 p.m. to discuss the company’s financial performance in Q4 and FY25.
Dial-In Information
Universal Access: +91 22 6280 1220, +91 22 7115 8122
International Numbers
US: 186 674 62133, UK: 080 8101 1573, Singapore: 800 101 2045, Hong Kong: 800 964 448
Emcure Pharmaceuticals Q3 Results
The company reported a 30.26% year-on-year (YoY) rise in its consolidated net profit to Rs 156 crore in Q3 FY25 from Rs 119.76 crore in Q3 FY24. Total income increased 16.8% YoY to Rs 1,966.53 crore in Q3 FY25 from Rs 1,683.4 crore in the year-ago period. Total expenses grew 15.33% YoY to Rs 1,736.6 crore in Q3 FY25 from Rs 1,505.7 crore in the same quarter of the preceding fiscal.
Emcure Pharmaceuticals Share Price History
The share price of the company has gained 0.25% in the past five trading sessions. In the last one month, Emcure Pharma's share price has fallen by 2.34%. The pharma stock has dropped nearly 18% in the last six months, while sliding 27.64% year-to-date.
Since its listing in July 2024, it touched a high of Rs 1,580 apiece on the NSE on Sep. 18, 2024. The stock hit a low of Rs 889 per share on April 7, 2025.
At 9:20 a.m. on Wednesday, Emcure Pharmaceuticals shares were trading 1.04% lower at Rs 1049.20 apiece on the NSE. This compares to a 0.19% rise in the benchmark Nifty 50.
